New Prenatal Study Challenges Folate Standard, Pits 5-MTHF vs. Folic Acid

LOS ANGELES, CA – May 07, 2026 – A new clinical trial is reigniting a critical conversation in prenatal nutrition, suggesting that a newer form of the essential B-vitamin folate may offer advantages over the long-standing gold standard. The study, funded by supplement brand Ritual in partnership with Brooklyn College (CUNY), found that using 5-methyltetrahydrofolate (5-MTHF) in prenatal multivitamins maintains necessary folate levels for mother and baby while significantly reducing the amount of unprocessed folic acid circulating in the body.

Published in the peer-reviewed journal Frontiers in Nutrition, the findings provide robust clinical evidence that could influence how prenatal supplements are formulated and chosen, adding weight to a growing trend toward more biologically active ingredients.

The Folate Debate: Folic Acid vs. 5-MTHF

Folate is a crucial nutrient during pregnancy, best known for its role in preventing devastating neural tube defects (NTDs) like spina bifida in a developing fetus. For decades, public health bodies like the Centers for Disease Control and Prevention (CDC) have recommended that all women of childbearing age consume 400 micrograms of folic acid—the stable, synthetic form of folate used in supplements and fortified foods. This strategy has been incredibly successful, dramatically reducing the incidence of NTDs.

However, folic acid is not the form of folate your cells use. The body must convert it through a multi-step process into the active form, 5-MTHF. This conversion process has a bottleneck, an enzyme called DHFR. When intake of folic acid is high, this enzyme can become saturated, leading to a buildup of unmetabolized folic acid (UMFA) in the bloodstream.

Concerns about UMFA are amplified by the fact that a significant portion of the population—estimated at 40-60%—has common genetic variations (in the MTHFR gene) that can impair their ability to efficiently convert folic acid to 5-MTHF. For these individuals, supplementation with the pre-converted, active 5-MTHF has been proposed as a more direct and potentially safer route to ensuring adequate folate status.

A Closer Look at the New Clinical Trial

The new study provides the most direct comparison to date of the two folate forms during the second and third trimesters. In a randomized, double-blind, controlled trial—the gold standard for clinical research—62 pregnant women were given a daily prenatal multivitamin containing either folic acid or 5-MTHF for 24 weeks.

"This study allows us to directly compare how different supplemental forms of folate are processed during pregnancy," said Dr. Xinyin Jiang, a professor at Brooklyn College (CUNY) and the study's principal investigator. "We found that 5-MTHF can maintain folate status just as effectively as folic acid, but with significantly less unmetabolized folic acid circulating in the body."

The results were striking:

• Equivalent Folate Status: There was no significant difference in total folate levels in the mother's blood, the placenta, or the cord blood between the two groups, indicating 5-MTHF was just as effective at its primary job.
• Reduced UMFA: Only 7% of the women in the 5-MTHF group had detectable levels of UMFA in their blood, compared to 31% in the folic acid group.
• Lower Concentrations: Among those with detectable levels, the UMFA concentrations were significantly lower in both maternal blood and the placenta for the 5-MTHF group.

Importantly, the study was designed to use doses that are equivalent on a dietary folate equivalent (DFE) basis, a standard measurement used by the National Institutes of Health.

The Question of UMFA: A Benign Biomarker or a Health Concern?

While the Ritual-backed study clearly shows 5-MTHF can minimize UMFA, the central question remains: does UMFA actually cause harm? The scientific community does not yet have a definitive answer. To date, no confirmed health risks have been directly attributed to UMFA at the levels achieved through recommended folic acid intake, and the benefit of folic acid in preventing NTDs is undisputed.

However, some observational studies have raised concerns, linking high UMFA levels to potential issues such as altered fetal gene expression and associations with certain health outcomes, though results have been inconsistent. Researchers are still investigating whether UMFA is simply a benign marker of excess intake or if it has biological consequences of its own. For now, minimizing its presence is seen by many as a prudent approach, especially when an effective alternative like 5-MTHF exists.

Raising the Bar: Transparency and Diversity in Supplement Research

Beyond the specific findings, the study highlights a broader movement within the supplement industry toward greater transparency and evidence-based formulation. Ritual, a Certified B Corporation, funded the study as part of a stated mission to challenge industry norms.

"As a founder and a mother, I am deeply aware that women's health, and specifically pregnancy, has long been underrepresented in clinical research," said Katerina Schneider, Founder and CEO of Ritual. "By intentionally funding research in these often-excluded populations, we aim to not only evaluate our own products but also to proactively raise the bar for the entire industry."

This commitment was reflected in the study's diverse cohort: 33.9% of participants identified as White, 29.0% as Black, 22.6% as Asian, and 34% as Hispanic or Latino. This diversity is critical for ensuring that nutritional findings are applicable across different populations, a long-standing gap in medical research.

"There are still major gaps in prenatal nutrition research, and we see a responsibility to help build that evidence base, particularly in diverse study populations," added Dr. Mastaneh Sharafi, Senior Vice President of Science & Innovation at Ritual. The company has pledged $5 million to complete clinical trials for its entire product portfolio by 2030.

Navigating the Prenatal Aisle: What This Means for Consumers

For expectant parents navigating the crowded prenatal vitamin aisle, the landscape is becoming more complex. While major health organizations like the CDC still officially recommend folic acid based on decades of NTD-prevention data, a growing number of brands, including Thorne, SmartyPants, and Garden of Life, have already shifted to using 5-MTHF, often marketing it as a premium, more bioavailable option.

Ritual's study adds a crucial piece of high-quality, peer-reviewed evidence to this trend. It demonstrates that for maintaining folate status in later pregnancy, 5-MTHF is a reliable alternative that comes with the added benefit of reducing exposure to unprocessed folic acid. This allows consumers and their healthcare providers to make more informed choices based on the latest science, contributing to an increasingly nuanced conversation about maternal and fetal health.